The fashion world has always had a complicated relationship with body size. For decades, the modeling industry has prized extreme thinness, with sample sizes hovering around zero. But the explosion of GLP-1 medications is introducing a powerful new shortcut to achieving and maintaining that coveted look. These drugs include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).
A recent Vogue article explores how these weight-loss drugs are influencing casting calls, runway shows, and the overall aesthetic of the industry. What was once achieved through rigorous dieting, exercise, or more extreme measures now has a pharmaceutical assist for many.
The Pressure Was Already There
Modeling has long demanded bodies that fit into tiny sample garments. Agents, designers, and casting directors have historically favored slimmer frames, often at great personal cost to the models. The rise of body positivity and size inclusivity in the late 2010s and early 2020s brought some progress, with more curvy models appearing in campaigns and on runways. In some instances it went too far, as some in the industry seemed to forget that customers want to see beauty, even if it came in other shapes and sizes. Now, recent seasons have shown a noticeable shift back toward uniformity and skinnier silhouettes.
GLP-1 drugs offer a tempting solution in this high-stakes environment. They suppress appetite dramatically, slow digestion, and can lead to significant weight loss, often 15 percent or more of body weight. For models who need to stay sample-size ready year-round, these medications can feel like a game-changer. They reduce the constant battle against hunger and yo-yo dieting. But is it healthy?
Impacts on Models and the Industry
Many in the industry are quietly using or considering GLP-1s. The result is a potential increase in the number of models who can maintain very low body weights more easily and consistently. This may contribute to the observed return of “heroin chic”–style thinness on some runways (we loved Kate Moss!!), with fewer curvy models booked and a narrower range of body types overall.
On the positive side, some argue that it allows models to focus more on their craft rather than obsessive calorie counting. However, concerns abound. Side effects like nausea, muscle loss, and fatigue can affect energy levels needed for long shoot days and travel. There are also ethical questions regarding health issues. And what happens to models who do not have access to these expensive treatments?
A Bigger Cultural Shift
This is not just about fashion. It is part of a larger societal change. As GLP-1 drugs become more accessible and affordable, the pressure to be thin is intensifying across industries, from Hollywood to corporate offices. In modeling, where appearance is the product, the impact is especially pronounced.
Experts and insiders worry about the long-term health implications for young models and the message this sends to the public. At the same time, some see it as a tool for better health management in a demanding profession. Models have gone to extreme measures in the past to stay thin, leading to eating disorders. Are GLP-1s a better option? We don’t know at this point.
Looking Ahead
The modeling industry stands at a crossroads. Will GLP-1s lock in a return to extreme thinness, or can the industry use this moment to promote healthier, more sustainable approaches to body management, with proper medical oversight, nutrition, and strength training to preserve muscle?
As these drugs continue to evolve, with new oral versions and combinations on the horizon, their influence on beauty standards will likely grow.
